MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Validation of the Short Progressive Supranuclear Palsy Quality of Life Scale in PSPNI

Q. Shen, XY. Li, J. Wang, FT. Liu (Shanghai, China)

Meeting: 2025 International Congress

Keywords: Progressive supranuclear palsy(PSP)

Category: MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales

Objective: This study aimed to evaluate the reliability, validity, and sensitivity to change of the PSP-ShoQoL in PSPNI, a longitudinal Chinese PSP cohort.

Background: Self-reported health-related quality of life (HR-QoL) has been increasingly recognized as an important measure in clinical trials for PSP. The Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) is the only disease-specific HRQoL tool, but it is lengthy and exhausting. To simplify assessment, the Short Progressive Supranuclear Palsy Quality of Life Scale (PSP-ShoQoL) was recently developed by Jensen et al.[1] However, it has not been validated in Chinese PSP patients.

Method: This retrospective study included 90 patients from the Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Patients were diagnosed and divided into the PSP-Richardson’s syndrome (PSP-RS) subgroup and the PSP-non-RS subgroup (including subtypes other than RS) according to the 2017 MDS criteria. HRQoL profiles of PSP patients were described. The psychometric properties of the PSP-ShoQoL were analyzed. Sensitivity to change of the PSP-ShoQoL was examined using one-year follow-up data. Multiple linear regression was used to investigate the determinants of HRQoL.

Results: The internal consistency of the PSP-ShoQoL was high (Cronbach’s α ≥ 0.70). The PSP-ShoQoL significantly correlated with the PSP-QoL and other HRQoL measures, as well as motor and non-motor scales (e.g., the PSP rating scale, Non-motor Symptoms Scale, Mini-Mental State Examination, and Geriatric Depression Scale), while no correlation was found with demographic information except disease duration. Sensitivity to change confirmed a significant decrease in HRQoL after a follow-up of median 13.0 months (P < 0.001). Disease severity, depression, and longer disease duration were identified as critical determinants of HRQoL.

Conclusion: The PSP-ShoQoL was a reliable and valid instrument for assessing HRQoL in PSP. It was sensitive to change and effectively captured the HRQoL profile as measured by the PSP-QoL.

References: [1] Jensen I, Stiel S, Bebermeier S, et al. A Short Progressive Supranuclear Palsy Quality of Life Scale. Mov Disord 2024; 39(9): 1602–9.

To cite this abstract in AMA style:

Q. Shen, XY. Li, J. Wang, FT. Liu. Validation of the Short Progressive Supranuclear Palsy Quality of Life Scale in PSPNI [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/validation-of-the-short-progressive-supranuclear-palsy-quality-of-life-scale-in-pspni/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/validation-of-the-short-progressive-supranuclear-palsy-quality-of-life-scale-in-pspni/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley